Nuvalent (NUVL) Financial Analysis & Valuation | Quarter Chart
Nuvalent (NUVL)
NUVLPrice: $103.77
Fair Value: 🔒
🔒score
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and rem... more
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with can... more
Description
Shares
| Market Cap | $7.63B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | James R. Porter |
| IPO Date | 2021-07-29 | CAGR | — |
| Employees | 162 | Website | www.nuvalent.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NUVL chart loading...
Fundamentals
Technicals
| Enterprise Value | $7.90B | P/E Ratio | — |
| Forward P/E | -29.9 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 6.95 |
| P/CF Ratio | -26.1 | P/FCF Ratio | -24.41 |
| EPS | $-6.06 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.43% | ROA | -0.34% |
| ROCE | -0.35% | Current Ratio | 16.14 |
| Quick Ratio | 16.14 | Cash Ratio | 1.97 |
| Debt/Equity | — | Interest Coverage | -34.11 |
| Altman Z Score | 27.57 | Piotroski Score | 2 |